Table 4.
Product | Dose | Model | Findings | Reference |
---|---|---|---|---|
Two SDB (different fermentation times: 4 h and 24 h) compared with yeast-fermented bread | One slice of bread (80 g) at 3-week intervals |
Clinical trial (36 healthy volunteers aged 20–31 years) Double-blind |
Highest satiety with SDB fermented for 24 h. In both SDB: faster gastric emptying, lower glycemic responses, higher concentration of total free amino acids and better digestibility | Rizzello et al., 2019 |
SDB (>12 h fermentation) compared with yeast-fermented bread | Six slices of the study bread (150 g)/day for 7 days |
Clinical trial (26 patients with IBS aged 18–65 years) Double-blind |
Higher reduction in ATIs to their monomeric form Lower levels of FODMAPs |
Laatikainen et al., 2017 |
Whole-grain rye SDB (40 h of fermentation) compared with yeast-fermented crispbread and unfermented rye crispbread | One slice (59.4 g) |
Clinical trial (24 healthy adults aged 18–70 years) Single-blind, cross-over trial |
Higher satiety and degradation of β-glucans | Zamaratskaia et al., 2017 |
SDB with low FODMAPs against regular rye SDB | 3.5–4 slices (105–120 g) of each bread/day in the 1st week 7–8 slices of SDB (210–240 g) per day from the 2nd to the 4th week |
Clinical trial (87 patients with IBS aged 18–65 years) Double-blind, placebo-controlled cross-over study |
Control of IBS symptoms and reduction of gastrointestinal gas accumulation Increase in dietary fiber intake and good acceptance |
Laatikainen et al., 2016 |
Whole-grain rye SDB compared with WB and rye-bran-enriched WB | 6–10 slices (25–30 g/slice) In two 4-week test periods |
Clinical trial (21 healthy subjects with mild gastrointestinal symptoms aged 38–65 years); Cross-over study |
Lower postprandial insulin concentration Improvement in the first-phase of insulin secretion Increase in postprandial concentrations of SCFAs |
Lappi et al., 2014 |
Wholegrain wheat SDB against WB | 6 slices (for women) and 7 (for men) of SDB per day (162.5 g) for 6 weeks |
Clinical trial (14 normoglycemic/normoinsulinemic adults and 14 hyperglycemic/hyperinsulinemic adults aged 43–70 years); Crossover study |
Improvement in glucose iAUC in response to an OGTT within hyperglycemic/hyperinsulinemic subjects | MacKay et al., 2012 |
Endosperm rye SDB compared with standard WB | One portion (50 g) at intervals of 1–2 weeks |
In vitro Starch and protein hydrolysis Clinical trial (16 healthy subjects aged 23 ± 3.7 years) |
Higher levels of total fiber and phenolic acids and a higher starch hydrolysis rate Lower postprandial insulin response Beneficial changes in plasma amino acids and their metabolites |
Bondia-Pons et al., 2011 |
Wholemeal wheat SDB (19.5 h fermentation) compared with WB, wholemeal wheat, and wholemeal wheat + xylanase | One slice with crust (50 g) of the test breads |
Clinical trial (11 insulin-resistant subjects, aged 40–65 years) |
Lowest postprandial glucose and insulin responses | Lappi et al., 2010 |
Two SDB compared with yeast-fermented wholemeal bread and yeast fermented WB | One slice (50 g) |
In vitro Starch hydrolysis Clinical trial (8 healthy volunteers aged 23–25 years) |
Significantly lower glycemic responses in SDB Resistant starch levels were higher in the SDB |
Scazzina et al., 2009 |
Whole wheat SDB (3 h fermentation) compared with whole wheat barley bread and WB | One slice (50 g) |
Clinical trial (10 overweight male subjects) Single-blind, cross-over |
Lower overall glucose and GLP-1 responses Lower glucose iAUC |
Najjar et al., 2008 |
SDB (24 h fermentation) with 4 flours compared with yeast-fermented 4-flour bread | A portion of 80 g for 2 days |
Clinical trial (17 celiac sprue patients) Double-blind |
Intestinal permeability not significantly different from baseline in 13 of the 17 patients | Di Cagno et al. (2004) |
SDB, Sourdough bread; WB, white bread; IBS, irritable bowel syndrome; ATIs, alpha-amylase/trypsin inhibitors; FODMAPs, Fermentable, Oligo-, Di-, and Mono-saccharides and Polyols; SCFAs, short-chain fatty Acids; OGTT, oral glucose tolerance test; iAUC, incremental area under the curve; GLP-1, glucagon-like peptide 1.